DK3395354T3 - Plasminogen til anvendelse i behandling af diabetisk nefropati - Google Patents
Plasminogen til anvendelse i behandling af diabetisk nefropati Download PDFInfo
- Publication number
- DK3395354T3 DK3395354T3 DK16874925.7T DK16874925T DK3395354T3 DK 3395354 T3 DK3395354 T3 DK 3395354T3 DK 16874925 T DK16874925 T DK 16874925T DK 3395354 T3 DK3395354 T3 DK 3395354T3
- Authority
- DK
- Denmark
- Prior art keywords
- plasminogen
- treatment
- diabetic nephropathy
- nephropathy
- diabetic
- Prior art date
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title 1
- 102000013566 Plasminogen Human genes 0.000 title 1
- 108010051456 Plasminogen Proteins 0.000 title 1
- 208000033679 diabetic kidney disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015097944 | 2015-12-18 | ||
PCT/CN2016/110450 WO2017101868A1 (zh) | 2015-12-18 | 2016-12-16 | 一种预防和治疗糖尿病肾病的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3395354T3 true DK3395354T3 (da) | 2024-06-03 |
Family
ID=59055777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16874925.7T DK3395354T3 (da) | 2015-12-18 | 2016-12-16 | Plasminogen til anvendelse i behandling af diabetisk nefropati |
Country Status (9)
Country | Link |
---|---|
US (1) | US11090372B2 (da) |
EP (1) | EP3395354B1 (da) |
JP (1) | JP6682008B2 (da) |
CN (1) | CN108778307A (da) |
CA (1) | CA3008686C (da) |
DK (1) | DK3395354T3 (da) |
ES (1) | ES2985007T3 (da) |
TW (1) | TWI725092B (da) |
WO (1) | WO2017101868A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
WO2017101872A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防和治疗宫颈糜烂的方法 |
EP3395354B1 (en) | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
CA3008691A1 (en) | 2015-12-18 | 2017-06-22 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
US11007253B2 (en) | 2015-12-18 | 2021-05-18 | Talengen International Limited | Method for preventing or treating radiation and chemical damage |
CA3008185C (en) | 2015-12-18 | 2024-01-16 | Talengen International Limited | Method for prevention or treatment of acute and chronic thrombosis |
CA3047175A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for mitigating heart disease |
CA3047176C (en) | 2016-12-15 | 2021-11-30 | Talengen International Limited | Use of plasminogen for promoting secretion of insulin in treatment of diabetes |
WO2018107687A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗高脂血症的方法 |
JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
WO2018233604A1 (zh) | 2017-06-19 | 2018-12-27 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r的方法和药物 |
CA3167202A1 (en) * | 2020-02-06 | 2021-08-12 | Jinan Li | Method and drug for preventing and treating multiple sclerosis |
JP2023521530A (ja) * | 2020-02-11 | 2023-05-25 | タレンゲン インターナショナル リミテッド | ウイルス性肺炎を治療する方法及び薬剤 |
CN115551534A (zh) * | 2020-02-26 | 2022-12-30 | 泰伦基国际有限公司 | 一种预防和治疗血压异常病症的方法和药物 |
CN114073526A (zh) * | 2020-08-21 | 2022-02-22 | 上海中医药大学附属曙光医院 | 一种基于磁共振弹性成像和血清学检查的肾纤维化评估方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ307044A (en) | 1995-04-26 | 2002-03-01 | Childrens Medical Center | Angiostatin fragments with antiangiogenic activity |
EP1001985A1 (en) | 1997-06-26 | 2000-05-24 | Karolinska Innovations AB | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
ES2276536T3 (es) | 1998-09-29 | 2007-06-16 | LEUVEN RESEARCH & DEVELOPMENT VZW | Uso de compuestos que reducen las alfas2-antiplasminas in vivo para la preparacion de una composicion para el tratamiento del ictus isquemico. |
WO2000044391A2 (en) | 1999-01-28 | 2000-08-03 | The Children's Medical Center Corporation | Plasminogen kringle 4 region fragments and methods of use |
US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
EP1227833A1 (en) | 1999-10-07 | 2002-08-07 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
TWI240723B (en) | 2001-06-20 | 2005-10-01 | Wyeth Corp | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
WO2003066842A2 (de) | 2002-02-06 | 2003-08-14 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen |
US6787135B2 (en) | 2002-03-13 | 2004-09-07 | William Beaumont Hospital | Modification of vitreal matrix metalloproteinase activity |
WO2004039956A2 (en) * | 2002-10-29 | 2004-05-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
CN1946352A (zh) | 2004-04-09 | 2007-04-11 | 狄科特康坦特公司 | 递送药物至眼以治疗后段疾病的方法和物品 |
MX2007002177A (es) | 2004-08-23 | 2007-04-02 | Wyeth Corp | Acidos de pirrolo-naftilo como inhibidores de pai-1. |
CN101039936A (zh) | 2004-08-23 | 2007-09-19 | 惠氏公司 | 作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸 |
EP2269623A1 (en) | 2005-04-29 | 2011-01-05 | The Regents of The University of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
CN101227918A (zh) | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
CN101263115A (zh) | 2005-08-17 | 2008-09-10 | 惠氏公司 | 经取代吲哚和其用途 |
WO2007051314A1 (en) | 2005-11-07 | 2007-05-10 | American Diagnostica Inc. | Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1 |
CN100529085C (zh) | 2005-12-30 | 2009-08-19 | 上海新生源医药研究有限公司 | 重组人纤溶酶原Kringle 5(hk5)生产方法 |
CN101002888A (zh) | 2006-01-16 | 2007-07-25 | 陈维森 | 复方糖尿康 |
US20070196350A1 (en) | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
MX2009002226A (es) * | 2006-08-28 | 2009-09-07 | Omnio Healer Ab | Candidatos contra infeccion. |
WO2009054439A1 (ja) | 2007-10-23 | 2009-04-30 | Institute Of Medicinal Molecular Design, Inc. | Pai-1産生抑制剤 |
KR101529743B1 (ko) | 2007-11-29 | 2015-06-17 | 그리폴스 테라퓨틱스 인코포레이티드 | 재조합적으로 변형된 플라스민 |
JP2009196927A (ja) | 2008-02-21 | 2009-09-03 | Chemo Sero Therapeut Res Inst | 血管障害に起因する網膜障害の進展阻害または治療剤 |
WO2011139973A2 (en) | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Methods of inhibiting fibrosis using anti-pai-1 antibodies |
CN102250210B (zh) | 2010-05-21 | 2014-05-28 | 厦门大学 | 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸 |
CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
BR112013017172A2 (pt) * | 2011-01-05 | 2016-10-11 | Thrombogenics Nv | variantes de plasminogênio e plasmina |
CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
KR20140064841A (ko) | 2011-08-12 | 2014-05-28 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 변이체 및 플라스민 변이체 |
DK2914575T3 (da) | 2012-10-31 | 2021-01-18 | Univ Michigan Regents | Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf |
US9079739B2 (en) | 2012-11-02 | 2015-07-14 | The Procter & Gamble Company | Apparatus for controlling the nip force/pressure between two rotating cylinders |
TW201734054A (zh) | 2013-08-13 | 2017-10-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途 |
SG10201710013RA (en) | 2013-08-13 | 2018-01-30 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
CN104789544B (zh) | 2014-01-16 | 2019-11-26 | 中国科学院福建物质结构研究所 | 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途 |
KR102692851B1 (ko) | 2014-12-19 | 2024-08-06 | 프로메틱 바이오 테라퓨틱스 인코포레이티드 | 플라스미노겐을 포함하는 약학 조성물 및 이의 용도 |
TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
EP3395354B1 (en) | 2015-12-18 | 2024-05-22 | Talengen International Limited | Plasminogen for use in treating diabetic nephropathy |
CA3008691A1 (en) * | 2015-12-18 | 2017-06-22 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
CA3008185C (en) * | 2015-12-18 | 2024-01-16 | Talengen International Limited | Method for prevention or treatment of acute and chronic thrombosis |
CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
CA3047176C (en) | 2016-12-15 | 2021-11-30 | Talengen International Limited | Use of plasminogen for promoting secretion of insulin in treatment of diabetes |
-
2016
- 2016-12-16 EP EP16874925.7A patent/EP3395354B1/en active Active
- 2016-12-16 US US16/062,049 patent/US11090372B2/en active Active
- 2016-12-16 DK DK16874925.7T patent/DK3395354T3/da active
- 2016-12-16 ES ES16874925T patent/ES2985007T3/es active Active
- 2016-12-16 JP JP2018550635A patent/JP6682008B2/ja active Active
- 2016-12-16 CN CN201680073672.2A patent/CN108778307A/zh active Pending
- 2016-12-16 CA CA3008686A patent/CA3008686C/en active Active
- 2016-12-16 WO PCT/CN2016/110450 patent/WO2017101868A1/zh active Application Filing
- 2016-12-16 TW TW105141898A patent/TWI725092B/zh active
Also Published As
Publication number | Publication date |
---|---|
EP3395354A1 (en) | 2018-10-31 |
JP2019500424A (ja) | 2019-01-10 |
WO2017101868A1 (zh) | 2017-06-22 |
US20190015485A1 (en) | 2019-01-17 |
CA3008686A1 (en) | 2017-06-22 |
EP3395354B1 (en) | 2024-05-22 |
CN108778307A (zh) | 2018-11-09 |
CA3008686C (en) | 2023-03-14 |
US11090372B2 (en) | 2021-08-17 |
EP3395354A4 (en) | 2019-06-12 |
TWI725092B (zh) | 2021-04-21 |
TW201722466A (zh) | 2017-07-01 |
ES2985007T3 (es) | 2024-10-31 |
JP6682008B2 (ja) | 2020-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3395354T3 (da) | Plasminogen til anvendelse i behandling af diabetisk nefropati | |
CY2021029I2 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
DK3391902T3 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
DK3191144T3 (da) | Medicinsk forbinding | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
DK3778595T3 (da) | Pancreatitisbehandling | |
DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3524255T3 (da) | Sammensætning til behandling af acne | |
DK3231444T3 (da) | Ny behandling | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3556383T5 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
DK3204038T3 (da) | Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus | |
DK4119569T3 (da) | Konjugerede antisense-forbindelser til anvendelse i behandling | |
DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte |